Table 1 The RMSD (Å) results of the structural superimposition between the individual RBDs of SARS-CoV-2 variants.

From: Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants

 

Wuhan-Hu-1

B.1.1.7

B.1.351

P.1

B.1.429

B.1.617.1

B.1.617.2

BA.1

BA.1.1

Wuhan-Hu-1

0.0

1.1

0.7

0.9

0.7

1.3

1.0

0.9

0.8

B.1.1.7

1.1

0.0

0.6

0.8

0.7

1.5

0.8

0.7

0.7

B.1.351

0.7

0.6

0.0

0.6

0.4

1.5

0.8

0.5

0.3

P.1

0.9

0.8

0.6

0.0

0.6

1.5

0.8

0.6

0.6

B.1.429

0.7

0.7

0.4

0.6

0.0

1.5

0.8

0.4

0.3

B.1.617.1

1.3

1.5

1.5

1.5

1.5

0.0

1.3

1.4

1.3

B.1.617.2

1.0

0.8

0.8

0.8

0.8

1.3

0.0

0.9

0.9

BA.1

0.9

0.7

0.5

0.6

0.4

1.4

0.9

0.0

0.5

BA.1.1

0.8

0.7

0.3

0.6

0.3

1.3

0.9

0.5

0.0

B.1.1.529

1.3

1.3

1.2

1.2

1.1

1.7

1.3

1.1

1.1

BA.2

1.1

1.3

0.9

0.9

0.9

1.5

1.0

0.8

1.0

BA.2.12.1

0.7

0.8

0.4

0.6

0.4

1.4

0.8

0.4

0.4

BA.2.13

1.2

1.0

1.0

1.0

1.0

1.6

1.1

1.0

1.1

BA.2.75

1.0

0.9

0.8

0.9

0.9

1.3

0.9

0.8

1.0

BA.3

1.5

1.2

1.2

1.2

1.1

1.6

1.9

1.2

1.3

BA.4

1.7

1.6

1.6

1.6

1.6

1.6

1.4

1.5

1.6

 

B.1.1.529

BA.2

BA.2.12.1

BA.2.13

BA.2.75

BA.3

BA.4

  

Wuhan-Hu-1

1.3

1.1

0.7

1.2

1.0

1.5

1.7

  

B.1.1.7

1.3

0.9

0.8

1.0

0.9

1.2

1.6

  

B.1.351

1.2

0.9

0.4

1.0

0.8

1.2

1.6

  

P.1

1.2

0.9

0.6

1.0

0.9

1.2

1.6

  

B.1.429

1.1

0.9

0.4

1.0

0.9

1.1

1.6

  

B.1.617.1

1.7

1.5

1.4

1.6

1.3

1.6

1.6

  

B.1.617.2

1.3

1.0

0.8

1.1

0.9

1.2

1.4

  

BA.1

1.1

0.8

0.4

1.0

0.8

1.2

1.5

  

BA.1.1

1.1

1.0

0.4

1.1

0.9

1.3

1.6

  

B.1.1.529

0.0

1.5

1.1

1.4

1.4

1.7

1.9

  

BA.2

1.5

0.0

1.0

0.9

0.9

0.9

1.4

  

BA.2.12.1

1.1

1.0

0.0

1.1

1.0

1.2

1.6

  

BA.2.13

1.4

0.9

1.1

0.0

0.9

1.1

1.4

  

BA.2.75

1.4

0.9

1.0

0.9

0.0

1.0

1.3

  

BA.3

1.7

0.9

1.2

1.1

1.0

0.0

1.5

  

BA.4

1.9

1.4

1.6

1.4

1.3

1.5

0.0